BioCentury
ARTICLE | Product Development

Buying proof of concept

Cephalon buys Gemin X after seeing undisclosed lung cancer data for obatoclax

March 28, 2011 7:00 AM UTC

The potent antagonism of obatoclax against MCL1 and a look at undisclosed survival data from a Phase IIb trial drove Cephalon Inc.'s decision to buy Gemin X Pharmaceuticals Inc. last week for $225 million and up to $300 million in milestones.

Obatoclax is a pan-inhibitor of anti-apoptotic proteins in the B cell lymphoma 2 (BCL2) family that initially is being developed to treat small cell lung cancer (SCLC)...